middle.news
Amplia and ANZGOG Launch PRROSE Trial Targeting Resistant Ovarian Cancer
8:52am on Friday 8th of May, 2026 AEST
•
Healthcare
Read Story
Amplia and ANZGOG Launch PRROSE Trial Targeting Resistant Ovarian Cancer
8:52am on Friday 8th of May, 2026 AEST
Key Points
PRROSE trial targets high-grade serous ovarian cancer
Narmafotinib combined with carboplatin and paclitaxel
Focus on patients resistant to platinum chemotherapy
Safety and biomarker analysis central to study
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE